Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system. Galway, Ireland-based Vivasure designed the latest-generation PerQseal Elite for percutaneous vessel closure. It leverages the legacy platform’s safety profile and ease of use while allowing for faster delivery. The system improves performance in calcium and the treatment of […]
Vivasure Medical
The biggest cardiovascular tech stories from TCT 2024
The 2024 edition of the Transcatheter Cardiovascular Therapeutics (TCT) conference once again highlighted significant innovations in cardiovascular care. This year’s event in Washington, D.C., featured company updates on all types of technologies, including heart valves, access and closure devices, drug-eluting implants, intravascular lithotripsy (IVL), renal denervation (RDN) and more. Some of the biggest names in […]
Vivasure reports positive PerQseal closure device study results
Vivasure Medical reported positive data from an FDA investigational device exemption (IDE) pivotal study evaluating its PerQseal closure device system. Initial results came from the PATCH pivotal study evaluating the safety and efficacy of PerQseal. Investigators presented findings at Transcatheter Cardiovascular Therapeutics (TCT) 2024 in Washington, D.C. Galway, Ireland-based Vivasure designed the latest-generation PerQseal Elite […]
Vivasure treats first patients with percutaneous vessel closure device
Vivasure Medical announced today that the first patient received treatment with its PerQseal Elite large-hole closure system. Galway, Ireland-based Vivasure designed the latest-generation PerQseal Elite for percutaneous vessel closure. It leverages the legacy platform’s safety profile and ease of use while allowing for faster delivery. The new system also improves performance in calcium and the […]
Vivasure wins FDA IDE approval, receives €30M from Haemonetics
Vivasure Medical announced today that it received FDA investigational device exemption (IDE) to advance a clinical study of its PerQseal device. Additionally, Galway, Ireland-based Vivasure announced a €30 million ($32.2 million) investment from Haemonetics. It marks part of the company’s Series D financing, for which the initial $23 million tranche closed in May 2022. The […]
Vivasure raises $23M initial Series D tranche; could reach up to $54M
Vivasure Medical announced today that it closed the first tranche — worth $23 million — of its Series D financing round. Galway, Ireland-based Vivasure’s $23 million (€22 million) fundraising tranche could make up a chunk of the Series D that could reach up to $54 million (€52 million) in total. According to a news release, […]
Vivasure treats first patient in U.S. study for next-gen PerQseal+ in TAVR procedures
Vivasure Medical announced today that the first patient was treated in a U.S. early feasibility study of its next-generation PerQseal+ device. Galway, Ireland-based Vivasure’s study will evaluate PerQseal+ in percutaneous transcatheter aortic valve replacement (TAVR) procedures. The first patient was treated by Dr. Robert Pyo at Stony Brook University Hospital in Stony Brook, New York. […]
Vivasure Medical initiates development of sutureless venous closure device
Vivasure Medical announced today that it launched a development program for its PerQseal Blue investigational product. Galway, Ireland-based Vivasure designed PerQseal Blue for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, including transcatheter mitral valve repair/replacement (TMVR) and transcatheter tricuspid valve repair/replacement (TTVR). According to a news release, the company based […]
